Antibodies against the novel coronavirus follow a classic pattern with a rapid increase within the first three weeks after symptoms, and detectable up to seven months post contracting the disease, according to a new study which assessed 300 patients infected with the virus and 198 post-COVID-19 volunteers.
"Our immune system recognises the virus SARS-CoV-2 as harmful and produces antibodies in response to it, which helps to fight the virus,"
Related News
Serum Institute of India, IAVI, and Merck join race to develop antibodies for Covid-19
To develop SARS-CoV-2 neutralising monoclonal antibodies (mAbs) that could help keep people healthy after they have been infected with the novel coronavirus, the Serum...
Live Mint 2020-10-22Researcher develops a fast, reliable test to quantify and assess effectiveness of Covid-19 antibodies
A scientist at the Seattle Children’s Research Institute says a cell-free test devised by him can assess effectiveness of Covid-19 bodies overnight as compared with other...
Business Line 2020-10-23We still don’t know what COVID-19 immunity means or how long it lasts
Even as U.S. President Donald Trump claims his bout with COVID-19 has granted him immunity, reports of people getting the disease a second time are emerging. While...
San Antonio Current 2020-10-24IAVI, Merck, and Serum Institute of India to develop monoclonal antibodies for Covid
New Delhi, Oct 22 : IAVI, a non-profit scientific research organisation and Serum Institute of India announced an agreement with Merck to develop SARS-CoV-2 neutralising...
The Siasat Daily 2020-10-22Antibodies Against Coronavirus Detectable Up to Seven Months Post COVID-19: Study
The study revealed that 90 per cent of subjects have detectable antibodies up to...
News18 2020-10-24Covid-19: IAVI, Merck, Serum join hands to develop monoclonal antibodies
IAVI, a non-profit scientific research organisation dedicated to addressing urgent and unmet global health challenges, and Pune-based Serum Institute of India Pvt Ltd, have...
Business Line 2020-10-22UK Vaccine Taskforce has selected Oxford Immunotec as the sole supplier of T cell testing for SARS-CoV-2 specific responses in new COVID vaccine trials
OXFORD, United Kingdom and MARLBOROUGH, Mass., October 22nd 2020 (GLOBE NEWSWIRE) – Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth...
Pharmiweb 2020-10-22